Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma

Zhejiang Cancer Hospital · 2026
ClinicalTrials.gov · Datasets · License: Public Domain · 2026
Open Source ↗
pirtobrutinib, sintilimab, central nervous system lymphoma, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 980916
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.